The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics

  • Lowest Price Guaranteed From USD 4,899

  • Published
    March 2020

  • Pages
    357

  • View Count
    1530

Example Insights

	Blood-Brain-Barrier -Context Blood-Brain-Barrier-Drug-Developers Blood-Brain-Barrier-Pipeline Blood-Brain-Barrier-Penetrating-drugs
Blood-Brain-Barrier-Competitiveness-analysis Blood-Brain-Barrier-Likely-partners Blood-Brain-Barrier-Patent-analysis Blood-Brain-Barrier-Funding-and-investments
Blood-Brain-Barrier-Market-forecast Blood-Brain-Barrier-Segmentation    

 

Overview

The commercial opportunities for BBB penetrating drugs are immense. I believe that if a drug developer has a viable technology and has established the necessary proof-of-concept, there is tremendous potential in terms of revenue generation

- Chief Operating officer, a Canada based Small-sized Company

According to a study conducted by the World Health Organization (WHO), diseases that affect the central nervous system (CNS), such as Alzheimer’s disease, brain cancer, multiple sclerosis. Parkinson’s disease and stroke, are characterized by a significant unmet need for effective treatment options. In 2019, it was reported that nearly 1.5 billion people suffer from some form of disorder affecting the CNS across the globe. In fact, the incidence of CNS disorders is anticipated to increase by 12% by 2030. In 2019, nearly 5.8 million Americans were reported to have been diagnosed with Alzheimer’s disease. Similarly, Parkinson’s disease was estimated to affect nearly one million people in America, with approximately 60,000 new patients being diagnosed every year. Further, experts believe that there is a critical relationship between recent pandemic of novel Coronavirus (COVID-19) and the cardiovascular and cerebrovascular systems. People suffering from certain CNS complications are at a relatively higher risk of COVID-19 infection due to a compromised immune system.

It is estimated that CNS disorders are responsible for a healthcare burden of nearly USD 2 trillion, in the US and Europe. Developing viable therapies against the aforementioned clinical conditions is largely complicated due to the elusive blood-brain barrier (BBB), a selectively permeable structure, which is very effective in preventing the entry of foreign substances, including drugs, into the brain. It has been reported that over 1,000 currently available / under development drugs targeting CNS disorders do not have the potential to target specific brain receptors responsible for the disease progression due to the hindrance by the BBB. Considering the serious physical, cognitive and psychosocial consequences that such indications have on patients, coupled to the alarming increase in their global prevalence, there is an urgent need for novel and effective treatment options that can cross the BBB. 

Over time, extensive R&D efforts have resulted in the development of a number of versatile BBB penetration technologies. These technologies have been designed either to externally alter the permeability of the BBB or augment the BBB penetrating capabilities of compatible pharmacological interventions. As a result, presently, there is a lot of enthusiasm within the medical science community related to these technologies. The growing interest in this field is also evident in the fact that over 1,200 modern scientific articles have been published (as observed on NCBI’s PubMed portal) over the last three years alone. However, it is worth mentioning that there are currently no approved BBB penetrating drugs available in the market. Currently, this niche market is driven by technology licensing activity, with drug developers collaborating with platform providers to grow their respective therapeutic pipelines. In fact, over the last 4-5 years, there has been a marked rise in the number of new entrants in this field. We anticipate this upcoming market to witness substantial growth in the coming years.

Scope of the Report

The ‘Blood-Brain Barrier (BBB) Market, 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics (2nd Edition) (based on Receptor Mediated Transcytosis, Trojan Horse, and Nanoparticle based Approaches)’ report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of BBB penetration technologies and affiliated drugs, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:

  • An overview of the overall landscape of BBB penetration technologies, featuring an in-depth analysis of the technologies based on a number of parameters, such as status of development (developed and under development), affiliated approach, type of compatible pharmacological molecule(s) crossing the BBB (small molecule and biologic), target receptor(s), target disease indication(s), patent availability, and licensing activity. In addition, it presents a detailed assessment of BBB technology developers and analyses based on parameters, such as year of establishment, company size, and location of headquarters.
  • A detailed assessment of the current market landscape of BBB penetrant drugs (based on the abovementioned technologies), providing information on drug developer(s) (such as year of establishment, company size, and location of headquarters), phase of development (clinical, preclinical, and discovery stage), type of molecule (small molecule and biologic), affiliated BBB penetration technology, route of administration (oral, intravenous, transmucosal and others), target disease indication(s), key therapeutic area(s), and information on special drug designation (if any). 
  • Identification of contemporary market trends, depicted using three schematic representations, which include [A] a tree map representation of the various industry players involved in the development of BBB penetrant drugs, distributed on the basis of the target disease indication(s) of pipeline candidates and size of the companies (small, mid-sized and large companies), [B] a bubble analysis comparing the leading players engaged in the development of BBB penetrant drugs, on the basis of parameters such as pipeline strength (based on the number of drug candidates developed by a particular company, across different phases of development), number of target disease indication(s) and the size of the developer company, and [C] an informative heptagon representation, highlighting the distribution of BBB penetrant drugs across popular target disease indication(s) (based on the number of drug candidates across each target disease indication).
  • An insightful competitiveness analysis of BBB penetration technologies, taking into consideration the supplier power (based on company size and years of experience in this field) and key technology specific information, such as type of compatible pharmacological molecule(s) crossing the BBB, availability of patent protection, number of deals signed for a particular technology (2014-2020 (till March)), and popularity of the technology (in terms of the number of drugs developed using the technology).
  • Elaborate profiles of prominent technology developers that are engaged in the development of at least four drugs (which are presently in both preclinical and clinical stages of development), featuring a brief overview of the company, its financial information (if available), BBB penetration technology overview, BBB penetrant product portfolio and an informed future outlook. 
  • An analysis of the partnerships that have been established in the domain, in the period between 2014 and 2020 (till March), covering product licensing agreements, technology licensing agreements, acquisitions and mergers, product development and commercialization agreements, research and development agreements, manufacturing agreements, service agreements and other agreements.
  • An elaborate discussion on the deal structures of various types of technology licensing agreements inked in this domain, including details of the rights associated with product ownership, associated royalties and upfront payments, and other contractual terms / conditions involved as a part of the agreement between various industry stakeholders.
  • An analysis of the investments made in the domain, in the period between 2014 and 2020 (till March), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in this field.
  • An in-depth analysis of the various patents that have been filed / granted related to BBB penetration technologies, till November 2019, taking into consideration various parameters, such as patent type, application year, issuing authority / patent offices involved, CPC symbols, emerging focus areas, type of organization and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.
  • An insightful chessboard analysis highlighting the most preferred / popular drug development strategies / paths adopted by majority of the drug developers (with clinical candidates) in order to progress their lead drug candidates.
  • An assessment of the most commonly targeted disorders affecting the CNS (shortlisted on the basis of number of BBB penetrant drugs in development), along with [A] an insightful 3D bubble chart highlighting the market potential of these disorders, based on the number of already approved drugs, number of pipeline drugs and the target patient population, and [B] an elaborate discussion on key epidemiological facts about specific diseases, causes, symptoms, details of BBB penetrant drugs that are being developed against them, currently available treatment options and details of already marketed drugs for each indication.
  • A list of 240+ drug developers targeting Alzheimer’s disease and Parkinson’s disease that are likely to partner with BBB penetration technology providers, and have been shortlisted on the basis of parameters, such as developer strength (based on company size and years of experience in this field), company’s pipeline strength and maturity (based on the number of drugs and affiliated stage of development), indication overlap, molecule type overlap, route of administration, mechanism of action, and the availability of in-house delivery technology.
  • A case study highlighting the working principle of the most common approaches that are being employed for the development of BBB penetration technologies, such as receptor mediated transcytosis (RMT) (including bispecific antibodies and molecular trojan horse mediated delivery either by direct coupling or using nanocarriers), increasing permeability to the BBB, passive diffusion approach, and other novel approaches (including cell-penetrating peptides, macrocycles, and organ-on-a-chip technology).
  • An informative analysis of contemporary Google Trends in the time period between 2015 and 2019 (till December) and insights generated from recent news articles related to the BBB, indicating the increasing popularity of this domain.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for BBB penetration technologies and affiliated therapeutics, over the next decade. Based on likely licensing deal structures and agreements that are expected to be inked in the foreseen future, we have provided an informed estimate of the evolution of the market for the period 2020-2030. In addition, we have provided information on (potential) sales-based revenues generated by BBB penetrant drugs that are currently in late stages of development for the treatment of different CNS disorders, based on parameters, such as target consumer segments, likely adoption rates, expected pricing and associated risk-adjustment sales opportunity. The report also features the likely distribution of the current and forecasted opportunity across [A] type of molecule (small molecules and biologics), [B] target disease indications (brain metastases in breast cancer, glioblastoma multiforme, Hurlers syndrome, and Hunter syndrome), [C] key contributing technologies, [D] leading drug developers, and [E] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In order to account for the uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. 

The opinions and insights presented in this study were also influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Ram Bhatt (Chief Executive Officer, Chairman and Founder, Innovative California Biosciences International (ICBI)) 
  • Frank S Walsh (Chief Executive Officer and Founder, Ossianix)
  • Pieter Gaillard (Chief Executive Officer and Co-Founder, 2-BBB)
  • Mathias Schmidt (Chief Executive Officer, ArmaGen)
  • Rob Hutchison (Chief Executive Officer and Chairman, biOasis Technologies)
  • Mark L Peterson (Chief Operating Officer, Cyclenium Pharma)
  • Xavier Rivero (Chief Operating Officer, Sagetis Biotech)
  • Carole Desseaux (Head of Clinical Affairs, CarThera)
  • Jamal Temsamani (Head of Drug Development, Vect-Horus)
  • Kevin Kit Parker (Professor, Wyss Institute, Harvard University)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading developers of BBB penetrating drugs and technologies?
  • What are the key BBB penetrating technologies (available / under development) for delivery of CNS drugs?
  • What are the key challenges faced by stakeholders engaged in this domain?
  • Which partnership models are commonly adopted by stakeholders in this industry?
  • Who are the most likely partners for BBB penetrating technology providers?
  • What different strategies are used by BBB drug developers?
  • What is the trend of capital investments in BBB related R&D?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of BBB penetration technologies and therapeutics market and its likely evolution in the short-mid term and long term. 

Chapter 3 is an introductory chapter that highlights important concepts related to the structure of human brain, its components and their functions in the central nervous system (CNS). It also presents an elaborate discussion on the different invasive and non-invasive strategies used to deliver drugs into the CNS. Further, the chapter provides an overview of the concept of BBB, historical evolution, including its role for efficient drug delivery. Furthermore, it provides information on the popular concepts used to develop BBB permeable drugs and technologies or to bypass the barrier. The chapter also includes a discussion on the key challenges associated with the use of BBB penetration technologies for efficient drug delivery to CNS. Additionally, it includes an analysis of contemporary Google Trends (till 2019) and insights from recent news articles related to the BBB, indicating the increasing popularity of this domain.

Chapter 4 provides a detailed overview of the overall landscape of BBB penetration technology providers. It features an in-depth analysis of the BBB penetration technologies, based on a number of parameters, such as status of development (developed and under development), affiliated approach, type of compatible pharmacological molecule(s) crossing the BBB (small molecule and biologic), target receptor(s), target disease indication(s), patent availability, and licensing activity. In addition, the chapter highlights a detailed landscape of BBB technology developers and analyses based on parameters, such as year of establishment, company size, and location of headquarters.

Chapter 5 includes a detailed assessment of the current market landscape of over 100 BBB penetrant drugs that are currently being evaluated in different stages of development. It features a comprehensive analysis of pipeline molecules based on their phase of development (clinical, preclinical, and discovery stage), type of molecule (small molecule and biologic), affiliated BBB penetration technology, route of administration (oral, intravenous, transmucosal and others), target disease indication(s), key therapeutic area(s), and information on special drug designation (if any). Further, the chapter provides information on drug developer(s), highlighting their year of establishment, company size, and location of headquarters. It also focuses on the identification of contemporary market trends, depicted using three schematic representations, which include [A] a tree map representation of the various industry players involved in the development of BBB penetrant drugs, distributed on the basis of the target disease indication(s) of pipeline candidates and size of the companies (small, mid-sized and large companies), [B] a bubble analysis comparing the leading players engaged in the development of BBB penetrant drugs, on the basis of parameters such as pipeline strength (based on the number of drug candidates developed by a particular company, across different phases of development), number of target disease indication(s) and the size of the developer company, and [C] an informative heptagon representation, highlighting the distribution of BBB penetrant drugs across popular target disease indication(s) (based on the number of drug candidates across each target disease indication).

Chapter 6 features elaborate profiles of prominent technology developers that are engaged in the development at least four drugs (which are presently in both preclinical and clinical stages of development). Each company profile features a brief overview of the company, its financial information (if available), BBB penetration technology overview, BBB penetrant product portfolio and an informed future outlook.
Chapter 7 presents a competitiveness analysis of BBB technologies, taking into consideration the supplier power (based on company size and years of experience in this field) and key technology specific information, such as type of compatible pharmacological molecule(s) crossing the BBB, availability of patent protection, number of deals signed for a particular technology (2014-2020 (till March)), and popularity of the technology (in terms of the number of drugs developed using the technology). The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.

Chapter 8 features a discussion on the working principle of the most common approaches being utilized for the development of BBB penetration  technologies, such as RMT (including bispecific antibodies and molecular trojan horse mediated delivery either by direct coupling or using nanocarriers), increasing permeability to the BBB, passive diffusion approach, and other novel approaches (including cell-penetrating peptides, macrocycles, and organ-on-a-chip technology).

Chapter 9 features an in-depth analysis and discussion on the various partnerships inked between the players in this market in the time period between 2014 and 2020 (till March), covering product licensing agreements, technology licensing agreements, acquisitions and mergers, product development and commercialization agreements, research and development agreements, manufacturing agreements, service agreements and other agreements.

Chapter 10 provides an elaborate discussion on the deal structures of various types of technology licensing agreements inked in this domain, including details of the rights associated with product ownership, associated royalties and upfront payments, and other contractual terms / conditions involved as a part of the agreement between various industry stakeholders.

Chapter 11 presents details on various investments received by companies that are focused on developing BBB penetration technologies and drugs. It also includes an analysis of the funding instances that have taken place in the market, up to 2020 (till March), highlighting the growing interest of the venture capital (VC) community and other strategic investors within this domain.

Chapter 12 provides an in-depth patent analysis to provide an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered those patents that have been filed / granted related to BBB penetration technologies till November 2019. The analysis also highlights the key trends associated with these patents, across patent type, application year, issuing authority / patent offices involved, CPC symbols, emerging focus areas, type of organization and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.

Chapter 13 features an insightful chessboard analysis highlighting the most preferred / popular drug development strategies / paths adopted by majority of the drug developers with clinical candidates engaged in this domain. The analysis was designed to enable stakeholder companies to improve their existing drug development strategies in order to accelerate the progress of their lead drug candidates.

Chapter 14 presents an insightful 3D bubble chart highlighting the market potential of the most commonly targeted disorders affecting the CNS (shortlisted on the basis of number of BBB penetrant drugs in development), based on the number of already approved drugs, number of pipeline drugs and the target patient population. It also includes an elaborate discussion on key epidemiological facts about specific diseases, causes, symptoms, details of BBB penetrant drugs that are being developed against them, currently available treatment options and details of already marketed drugs for each respective indication.

Chapter 15 presents a list of 240+ drug developers targeting Alzheimer’s disease and Parkinson’s disease that are likely to partner with BBB penetration technology providers, and have been shortlisted on the basis of parameters, such as developer strength (based on company size and years of experience in this field), company’s pipeline strength and maturity (based on the number of drugs and affiliated stage of development), indication overlap, molecule type overlap, route of administration, mechanism of action, and the availability of in-house delivery technology.

Chapter 16 features a comprehensive market forecast, highlighting the future potential of this market till 2030 based on likely licensing deal structures and agreements that are expected to be signed in the foreseen future. In addition, we have provided information on (potential) sales-based revenues generated by BBB penetrant drugs that are currently in late stages of development for the treatment of different CNS disorders, based on parameters, such as target consumer segments, likely adoption rates, expected pricing and associated risk-adjustment sales opportunity. The chapter also features the likely distribution of the current and  forecasted opportunity across [A] type of molecule (small molecules and biologics), [B] target disease indications (brain metastases in breast cancer, glioblastoma multiforme, Hurlers syndrome, and Hunter syndrome), [C] key contributing technologies, [D] leading drug developers, and [E] key geographical regions (North America, Europe, Asia-Pacific and rest of the world).

Chapter 17 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 18 is a collection of interview transcripts of discussions held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Ram Bhatt (CEO, Chairman and Founder, Innovative California Biosciences International (ICBI)), Frank S Walsh (CEO and Founder, Ossianix), Pieter Gaillard (CEO And Co-Founder, 2-BBB), Mathias Schmidt (CEO, ArmaGen), Rob Hutchison (CEO and Chairman, biOasis Technologies), Mark L Peterson (Chief Operating Officer, Cyclenium Pharma), Xavier Rivero (Chief Operating Officer, Sagetis Biotech), Carole Desseaux (Head of Clinical Affairs, CarThera), Jamal Temsamani (Head of Drug Development, Vect-Horus), and Kevin Kit Parker (Professor, Wyss Institute, Harvard University)

Chapter 19 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 20 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Structure of the Human Brain
3.3. Global Burden on Neurological Disorders and Impact of Coronavirus Disease (COVID-19)

3.4. Strategies for Drug Delivery to the Central Nervous System (CNS)
3.4.1. Invasive Techniques
3.4.1.1. Systemic Administration of Therapeutics
3.4.1.2. Direct Administration of Therapeutics
3.4.1.3. Intracerebral Devices and Implants

3.4.2. Non-Invasive Techniques / Approaches
3.4.2.1. Liposomes
3.4.2.2. Exosomes
3.4.2.3. Prodrugs
3.4.2.4. Nanoparticles and Microspheres
3.4.2.5. Novel Formulations and Conjugates
3.4.3. Chemical Delivery Systems

3.5. Blood-Brain Barrier (BBB)
3.5.1. Key Historical Milestones
3.5.2. Structure and Key Components
3.5.3. Key Functions

3.6. Strategies for Drug Delivery across the BBB
3.6.1. Increasing Permeability by Temporary Disruption of the BBB
3.6.2. Pharmacological Strategies to Facilitate Transport Across the BBB
3.7. Challenges Associated with BBB Penetration and CNS Drug Delivery

3.8. Prevalent Trends Related to Non-Invasive BBB Penetration Technologies
3.8.1. Emerging Focus Areas
3.8.2. Key Historical Trends
3.8.3. Geographical Activity
3.9. Concluding Remarks

4. MARKET LANDSCAPE: NON-INVASIVE BBB PENETRATION 
4.1. Chapter Overview
4.2. Non-Invasive BBB Penetration Technologies: Overall Market Landscape 
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Underlying Principle
4.2.3. Analysis by Compatible Pharmacological Molecule(s) 
4.2.4. Analysis by Target Receptor(s)
4.2.5. Analysis by Target Disease Indication(s)
4.2.6. Analysis by Patent Availability
4.2.7. Analysis by Licensing Activity

4.3. Non-Invasive BBB Penetration Technology Providers: Overall Market Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters

5. MARKET LANDSCAPE: BBB PENETRATING DRUGS
5.1. Chapter Overview
5.2. BBB Penetrating Drugs: Development Pipeline 
5.2.1. Analysis by Phase of Development
5.2.2. Analysis by Type of Molecule
5.2.3. Analysis by Affiliated BBB Penetration Technology
5.2.4. Analysis by Route of Administration
5.2.5. Analysis by Target Disease Indication(s)
5.2.6. Analysis by Therapeutic Area(s)
5.3. BBB Penetrating Drugs: Additional Information

5.4. BBB Penetrating Drug Developers: Overall Market Landscape
5.4.1. Analysis by Year of Establishment
5.4.2. Analysis by Company Size
5.4.3. Analysis by Location of Headquarters
5.4.4. Leading Drug Developers: Analysis by Number of Drugs
5.4.5. Leading Drug Developers: 4D Bubble Analysis based on Pipeline Strength, Target Disease Indication and Company Size
5.4.6. Heptagon Representation: Analysis by Phase of Development and Key Disease Indications
5.4.7. Tree Map Representation: Analysis by Key Disease Indications and Size of the Company

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Leading Players based in North America

6.2.1. Angiochem
6.2.1.1. Company Overview
6.2.1.2. Technology Overview
6.2.1.3. Product Portfolio
6.2.1.4. Recent Developments and Future Outlook

6.2.2. ArmaGen
6.2.2.1. Company Overview
6.2.2.2. Technology Overview
6.2.2.3. Product Portfolio
6.2.2.4. Recent Developments and Future Outlook

6.2.3. Denali Therapeutics
6.2.3.1. Company Overview
6.2.3.2. Technology Overview
6.2.3.3. Product Portfolio
6.2.3.4. Recent Developments and Future Outlook

6.2.4. ICB International
6.2.4.1. Company Overview
6.2.4.2. Technology Overview
6.5.4.3. Product Portfolio
6.2.4.4. Recent Developments and Future Outlook

6.2.5. Lauren Sciences
6.2.5.1. Company Overview
6.2.5.2. Technology Overview
6.2.5.3. Product Portfolio
6.2.5.4. Recent Developments and Future Outlook

6.3. Leading Players based in Europe
6.3.1. BioArctic
6.3.1.1. Company Overview
6.3.1.2. Technology Overview
6.3.1.3. Product Portfolio
6.3.1.4. Recent Developments and Future Outlook

6.3.2. Cyclenium Pharma
6.3.2.1. Company Overview
6.3.2.2. Technology Overview
6.3.2.3. Product Portfolio
6.3.2.4. Recent Developments and Future Outlook

6.3.3. Iproteos
6.3.3.1. Company Overview
6.3.3.2. Technology Overview
6.3.3.3. Product Portfolio
6.3.3.4. Recent Developments and Future Outlook

6.3.4. Medesis Pharma
6.3.4.1. Company Overview
6.3.4.2. Technology Overview
6.3.4.3. Product Portfolio
6.3.4.4. Recent Developments and Future Outlook

6.3.5. Ossianix
6.3.5.1. Company Overview
6.3.5.2. Technology Overview
6.3.5.3. Product Portfolio
6.3.5.4. Recent Developments and Future Outlook

6.3.6. Vect-Horus
6.3.6.1. Company Overview
6.3.6.2. Technology Overview
6.3.6.3. Product Portfolio
6.3.6.4. Recent Developments and Future Outlook

6.4. Leading Players based in Asia-Pacific
6.4.1. JCR Pharmaceuticals
6.4.1.1. Company Overview
6.4.1.2. Technology Overview
6.4.1.3. Product Portfolio
6.4.1.4. Recent Developments and Future Outlook

7. TECHNOLOGY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Methodology and Key Parameters
7.3. BBB Penetration Technologies: Platform Competitiveness Analysis

8. NON-INVASIVE BBB PENETRATION TECHNOLOGIES: POPULAR APPROACHES
8.1. Chapter overview
8.2. Receptor Mediated Transcytosis (RMT)
8.2.1. Type of Target Receptors
8.2.1.1. Diphtheria Toxin Receptor
8.2.1.2. Insulin Receptor and Insulin-like Growth Factor Receptor
8.2.1.3. Low Density Lipoprotein Receptor-Related Proteins (LRP-1 and LRP-2)
8.2.1.4. Transferrin Receptor

8.2.2. Types of RMT Approaches
8.2.2.1. Bispecific Antibody-based Approach
8.2.2.2. Molecular Trojan Horse-based Approach
8.2.2.2.1. Important Considerations for Designing Molecular Trojan Horses
8.2.2.2.2. Considerations for Designing a Trojan Horse Liposome (THL)
8.2.2.2.3. Popular Conjugation Strategies
8.2.2.2.3.1. Direct Coupling Approach
8.2.2.2.3.2. Nanoparticles-based Approach

8.3. Increasing the Permeability of the BBB
8.3.1. Use of Ultrasound Waves
8.3.2. Use of High-Frequency Electric Field

8.4. Passive Diffusion

8.5. Novel Approaches
8.5.1. Cell Penetrating Peptides
8.5.2. Macrocycles
8.5.3. Organ-on-a-Chip Technology

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models

9.3. Non-Invasive BBB Technologies and Drugs: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Focus Area
9.3.6. Analysis by Type of Molecule
9.3.7. Analysis by Target Disease Indication
9.3.8. Most Active Players: Analysis by Number of Partnerships
9.3.9. Most Popular Technologies: Analysis by Number of Partnerships
9.3.10. Regional Analysis
9.3.11. Intercontinental and Intracontinental Agreements

10. ANALYSIS OF RECENT LICENSING AGREEMENTS
10.1. Chapter Overview
10.2. Licensing Agreements: Definition and Importance in Pharmaceutical Industry

10.3. Types of Licensing Agreements
10.3.1. Out-Licensing Agreements
10.3.2. In-Licensing Agreements

10.4. Components of Licensing Agreements

10.5. Recent Examples of BBB-Related Technology Licensing Agreements
10.5.1. Analysis by Year of Agreement
10.5.2. Analysis by Type of Licensing Agreement
10.5.3. Analysis by Type of Owner
10.5.4. Most Active Players: Analysis by Number of Licensing Agreements
10.5.5. Most Popular Technologies: Analysis by Number of Licensing Agreements
10.5.6. Regional Analysis
10.5.7. Intercontinental and Intracontinental Licensing Agreements

10.6. Case-in-Point: Technology Licensing Timeline
10.6.1. Sumitomo Dainippon Pharma and JCR Pharmaceuticals
10.6.2. Denali Therapeutics and Sanofi
10.6.3. biOasis Technologies and Prothena
10.6.4. Vect-Horus and Janssen Pharmaceuticals
10.7. Concluding Remarks

11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Non-Invasive BBB Penetration Technologies and Drugs: List of Funding and Investments
11.3.1. Analysis by Number of Instances
11.3.2. Analysis by Amount Invested
11.3.3. Analysis by Type of Funding
11.3.4. Analysis by Type of Company
11.3.5. Analysis by Purpose of Funding
11.3.6. Analysis by Type of Molecule
11.3.7. Analysis by Target Disease Indication 
11.3.8. Analysis by Geography
11.3.9. Most Active Players: Analysis by Number of Funding Instances
11.3.10. Most Popular Technologies: Analysis by Number of Funding Instances
11.3.11. Most Active Investors: Analysis by Number of Funding Instances
11.4. Concluding Remarks

12. PATENT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Non-Invasive BBB Penetration Technologies: Patent Analysis
12.3.1. Analysis by Application Year
12.3.1.1. Analysis by Filed Patent Applications
12.3.1.2. Analysis by Granted Patent Applications

12.3.2. Analysis by Issuing Authority / Patent Offices Involved
12.3.3. Analysis by CPC Symbols
12.3.4. Emerging Focus Areas
12.3.5. Analysis by Type of Organization
12.3.6. Leading Assignees: Analysis by Number of Patents

12.4. Non-Invasive BBB Technologies: Patent Valuation Analysis

13. DRUG DEVELOPMENT STRATEGY ANALYSIS
13.1. Chapter Overview
13.2 Scope and Methodology
13.3. Strategies Adopted by Late-Stage Drug Candidates
13.3.1. Drug A
13.3.2. Drug B
13.3.3. Drug C
13.3.4. Drug D

13.4. Concluding Remarks

14. MARKET POTENTIAL OF KEY NEUROLOGICAL DISORDERS
14.1. Chapter Overview
14.2. Market Potential of Key Neurological Disorders: 3D Bubble Chart Analysis
14.3. Key Neurological Disorders: Detailed Information

14.3.1. Alzheimer’s Disease
14.3.1.1. Disease Description
14.3.1.2. Epidemiology
14.3.1.3. Symptoms
14.3.1.4. Current Treatment Options
14.3.1.5. BBB Penetrating Drugs for Alzheimer’s Disease
14.3.1.6. Roots Analysis Perspective

14.3.2. Brain Cancer
14.3.2.1. Disease Description
14.3.2.2. Epidemiology
14.3.2.3. Symptoms
14.3.2.4. Current Treatment Options
14.3.2.4.1. Surgery
14.3.2.4.2. Radiation Therapy
14.3.2.4.3. Systemic Therapy

14.3.2.5. BBB Penetrating Drugs for Brain Cancer
14.3.2.6. Roots Analysis Perspective

14.3.3. Multiple Sclerosis
14.3.3.1. Disease Description
14.3.3.2. Epidemiology
14.3.3.3. Symptoms
14.3.3.4. Current Treatment Options
14.3.3.4.1. Treatment for Attacks
14.3.3.4.2. Treatments to Modify Progression
14.3.3.4.3. Interferons
14.3.3.5. BBB Penetrating Drugs for Multiple Sclerosis
14.3.3.6. Roots Analysis Perspective

14.3.4. Parkinson’s Disease
14.3.4.1. Disease Description
14.3.4.2. Epidemiology
14.3.4.3. Symptoms
14.3.4.4. Current Treatment Options
14.3.4.4.1. Pharmacological Management of Parkinson’s Disease
14.3.4.4.2. Non-Pharmacological Management of Parkinson’s Disease
14.3.4.4.3. Management of Parkinson’s Disease using Dietary Supplements

14.3.4.5. BBB Penetrating Drugs for Parkinson’s Disease
14.3.4.6. Roots Analysis Perspective

15. LIKELY PARTNER ANALYSIS
15.1. Chapter Overview
15.2. Scope and Methodology

15.3. Potential Strategic Partners for Drug Development
15.3.1. Opportunities in North America
15.3.1.1. Most Likely Partners
15.3.1.2. Likely Partners
15.3.1.3. Less Likely Partners

15.3.2. Opportunities in Europe
15.3.2.1. Most Likely Partners
15.3.2.2. Likely Partners
15.3.2.3. Less Likely Partners
15.3.3. Opportunities in Asia-Pacific and Rest of the World
15.3.3.1. Most Likely Partners
15.3.3.2. Likely Partners
15.3.3.3. Less Likely Partners

16. MARKET FORECAST
16.1. Chapter Overview
16.2. Forecast Methodology and Key Assumptions
16.3. Overall BBB Penetration Technologies Market, 2020-2030
16.3.1. BBB Penetration Technologies Market: Contribution from Upfront Payments, 2020-2030
16.3.2. BBB Penetration Technologies Contribution from Milestone Payments, 2020-2030

16.4. Overall BBB Penetrating Drugs Market, 2020-2030
16.4.1. BBB Penetrating Drugs Market: Distribution by Type of Molecule
16.4.1.1. BBB Penetrating Drugs Market for Small Molecules, 2020-2030
16.4.1.2. BBB Penetrating Drugs Market for Biologics, 2020-2030

16.4.2. BBB Penetrating Drugs Market: Distribution by Target Disease Indication
16.4.2.1. BBB Penetrating Drugs Market for Brain Metastases in Breast Cancer, 2020-2030
16.4.2.2. BBB Penetrating Drugs Market for Glioblastoma Multiforme, 2020-2030
16.4.2.3. BBB Penetrating Drugs Market for Hunter Syndrome, 2020-2030
16.4.2.4. BBB Penetrating Drugs Market for Hurler Syndrome, 2020-2030

16.4.3. BBB Penetrating Drugs Market: Distribution by Key Geographical Regions
16.4.3.1. BBB Penetrating Drugs Market in North America, 2020-2030
16.4.3.2. BBB Penetrating Drugs Market in Europe, 2020-2030
16.4.3.3. BBB Penetrating Drugs Market in Asia-Pacific and Rest of the World, 2020-2030

16.4.4. BBB Penetrating Drugs Market: Distribution by Leading Technology Platforms
16.4.5. BBB Penetrating Drugs Market: Distribution by Leading Drug Developers

16.5.6. Drug-wise Sales Forecast
16.5.6.1. 2B3-101 / 2X-111 (2X Oncology)
16.5.6.1.1. Sales Forecast (USD Million)
16.5.6.1.2. Risk-Adjusted Market Opportunity (USD Million)
16.5.6.1.3. Net Present Value (USD Million)
16.5.6.1.4. Value Creation Analysis

16.5.6.2. AGT-181 (ArmaGen)
16.5.6.2.1. Sales Forecast (USD Million)
16.5.6.2.2. Risk-Adjusted Market Opportunity (USD Million)
16.5.6.2.3. Net Present Value (USD Million)
16.5.6.2.4. Value Creation Analysis

16.5.6.3. AGT-182 (ArmaGen)
16.5.6.3.1. Sales Forecast (USD Million)
16.5.6.3.2. Risk-Adjusted Market Opportunity (USD Million)
16.5.6.3.3. Net Present Value (USD Million)
16.5.6.3.4. Value Creation Analysis

16.5.6.4. ANG1005 (Angiochem)
16.5.6.4.1. Sales Forecast (USD Million)
16.5.6.4.2. Risk-Adjusted Market Opportunity (USD Million)
16.5.6.4.3. Net Present Value (USD Million)
16.5.6.4.4. Value Creation Analysis

16.5.6.5. JR-141 (JCR Pharmaceuticals)
16.5.6.5.1. Sales Forecast (USD Million)
16.5.6.5.2. Risk-Adjusted Market Opportunity (USD Million)
16.5.6.5.3. Net Present Value (USD Million)
16.5.6.5.4. Value Creation Analysis

17. CONCLUSION
17.1. Chapter Overview
17.2. Key Takeaways

18. EXECUTIVE INSIGHTS
18.1. Chapter Overview
18.2. Innovative California Biosciences International (ICBI)
18.2.1. Company Snapshot
18.2.2. Interview Transcript: Ram Bhatt, Chief Executive Officer, Chairman and Founder

18.3. Ossianix
18.3.1. Company Snapshot
18.3.2. Interview Transcript: Frank S Walsh, Chief Executive Officer and Founder

18.4. 2-BBB
18.4.1. Company Snapshot
18.4.2. Interview Transcript: Pieter Gaillard, Chief Executive Officer and Co-Founder

18.5. ArmaGen
18.5.1. Company Snapshot
18.5.2. Interview Transcript: Mathias Schmidt, Chief Executive Officer

18.6. biOasis Technologies
18.6.1. Company Snapshot
18.6.2. Interview Transcript: Rob Hutchison, Chief Executive Officer

18.7. Cyclenium Pharma
18.7.1. Company Snapshot
18.7.2. Interview Transcript: Mark L Peterson, Chief Operating Officer

18.8. Sagetis Biotech
18.8.1. Company Snapshot
18.8.2. Interview Transcript: Xavier Rivero, Chief Operating Officer

18.9. CarThera
18.9.1. Company Snapshot
18.9.2. Interview Transcript: Carole Desseaux, Head of Clinical Affairs

18.10. Vect-Horus
18.10.1. Company Snapshot
18.10.2. Interview Transcript: Jamal Temsamani, Head of Drug Development

18.11. Wyss Institute, Harvard University
18.11.1. Organization Snapshot
18.11.2. Interview Transcript: Kevin Kit Parker, Professor

19. APPENDIX I: TABULATED DATA

20. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Structure of the Human Brain
Figure 3.2 Common Neurological Disorders
Figure 3.3 Important Statistics Related to Neurological Disorders
Figure 3.4 Strategies for Drug Delivery to the Central Nervous System (CNS)
Figure 3.5 Key Historical Milestones in BBB Research
Figure 3.6 Pathway Associated with the BBB
Figure 3.7 Transport Systems Associated with the BBB
Figure 3.8 Google Trends Analysis: Emerging Focus Areas
Figure 3.9 Google Trends Analysis: Historical Timeline
Figure 3.10 Google Trends Analysis: Geographical Activity
Figure 4.1 Non-Invasive BBB Penetration Technologies: Distribution by Status of Development
Figure 4.2 Non-Invasive BBB Penetration Technologies: Distribution by Underlying Principle
Figure 4.3 Non-Invasive BBB Penetration Technologies: Distribution by Compatible Pharmacological Molecule(s)
Figure 4.4 Non-Invasive BBB Penetration Technologies: Distribution by Target Receptor(s)
Figure 4.5 Non-Invasive BBB Penetration Technologies: Distribution by Target Disease Indication(s)
Figure 4.6 Non-Invasive BBB Penetration Technologies: Distribution by Patent Availability
Figure 4.7 Non-Invasive BBB Penetration Technologies: Distribution by Licensing Activity
Figure 4.8 Non-Invasive BBB Technology Providers: Distribution by Year of Establishment
Figure 4.9 Non-Invasive BBB Technology Providers: Distribution by Company Size
Figure 4.10 Non-Invasive BBB Technology Providers: Distribution by Location of Headquarters
Figure 5.1 BBB Penetrating Drugs: Distribution by Phase of Development
Figure 5.2 BBB Penetrating Drugs: Distribution by Type of Molecule
Figure 5.3 BBB Penetrating Drugs: Distribution by Affiliated BBB Penetration Technology
Figure 5.4 BBB Penetrating Drugs: Distribution by Route of Administration
Figure 5.5 BBB Penetrating Drugs: Distribution by Target Disease Indication(s)
Figure 5.6 BBB Penetrating Drugs: Distribution by Therapeutic Area(s)
Figure 5.7 BBB Penetrating Drug Developers: Distribution by Year of Establishment
Figure 5.8 BBB Penetrating Drug Developers: Distribution by Company Size
Figure 5.9 BBB Penetrating Drug Developers: Distribution by Location of Headquarters
Figure 5.10 Leading Drug Developers: Distribution by Number of Drugs
Figure 5.11 Leading Drug Developers: 4D Bubble Analysis based on Pipeline Strength, Target Disease Indication and Company Size
Figure 5.12 Heptagon Representation: Distribution by Phase of Development and Key Disease Indications
Figure 5.13 Tree Map Representation: Distribution by Key Disease Indications and Size of the Company
Figure 7.1 BBB Penetration Technologies: Platform Competitiveness Analysis
Figure 8.1 Receptor Mediated Transcytosis (RMT): Key Functions
Figure 8.2 RMT: Working Mechanism
Figure 8.3 Molecular Trojan Horse-based Approach: Working Mechanism
Figure 9.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2014-Q1 2020
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Year-Wise Trend by Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.5 Partnerships and Collaborations: Year-Wise Trend by Type of Partner
Figure 9.6 Partnerships and Collaborations: Distribution by Type of Partner and Partnership Model
Figure 9.7 Partnerships and Collaborations: Distribution by Focus Area
Figure 9.8 Partnerships and Collaborations: Distribution by Type of Molecule
Figure 9.9 Partnerships and Collaborations: Year-Wise Trend by Type of Molecule
Figure 9.10 Partnerships and Collaborations: Distribution by Target Disease Indication
Figure 9.11 Partnerships and Collaborations: Year-Wise Trend by Target Disease Indication
Figure 9.12 Partnerships and Collaborations: Distribution by Target Disease Indication and Partnership Model
Figure 9.13 Most Active Players: Distribution by Number of Partnerships
Figure 9.14 Most Popular Technologies: Distribution by Number of Partnerships
Figure 9.15 Partnerships and Collaborations: Regional Distribution
Figure 9.16 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.1 Key Risks and Benefits Associated with a Licensee
Figure 10.2 Key Risks and Benefits Associated with a Licensor
Figure 10.3 Licensing Agreements: Distribution of Financial Components
Figure 10.4 BBB-Related Technology Licensing Agreements: Cumulative Year-Wise Trend, Pre-2014-Q1 2020
Figure 10.5 BBB-Related Technology Licensing Agreements: Distribution by Type of Licensing Agreement
Figure 10.6 BBB-Related Technology Licensing Agreements: Distribution by Type of Owner
Figure 10.7 Most Active Players: Distribution by Number of Licensing Agreements
Figure 10.8 BBB-Related Technology Licensing Agreements: Regional Analysis
Figure 10.9 BBB-Related Technology Licensing Agreements: Intercontinental and Intracontinental Agreements
Figure 10.10 BBB-Related Technology Licensing Agreements: Technology Providers’ Perspective
Figure 11.1 Funding and Investment Analysis: Distribution of Companies by Year of Establishment and Type of Funding, Pre-2014-Q1 2020
Figure 11.2 Funding and Investment Analysis: Cumulative Number of Instances by Year, Pre-2014-Q1 2020
Figure 11.3 Funding and Investment Analysis: Distribution by Type of Funding and Year of Investment, Pre-2014-Q1 2020
Figure 11.4 Funding and Investment Analysis: Cumulative Amount Invested, Pre-2014-Q1 2020 (USD Million)
Figure 11.5 Funding and Investment Analysis: Year-Wise Distribution by Amount Invested and Type of Funding, Pre-2014-Q1 2020 (USD Million)
Figure 11.6 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Pre-2014-Q1 2020
Figure 11.7 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, Pre-2014-Q1 2020 (USD Million)
Figure 11.8 Funding and Investment Analysis: Summary of Amount Invested, Pre-2014-Q1 2020 (USD Million)
Figure 11.9 Funding and Investment Analysis: Distribution by Total Amount Invested and Type of Company, Pre-2014-Q1 2020 (USD Million)
Figure 11.10 Funding and Investment Analysis: Distribution of the Total Amount Invested by Purpose of Funding, Pre-2014-Q1 2020 (USD Million)
Figure 11.11 Funding and Investment Analysis: Distribution of Instances by Type of Molecule, Pre-2014-Q1 2020
Figure 11.12 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Molecule, Pre-2014-Q1 2020 (USD Million)
Figure 11.13 Funding and Investment Analysis: Distribution by Target Disease Indication
Figure 11.14 Funding and Investment Analysis: Distribution of the Total Amount Invested by Target Disease Indication, Pre-2014-Q1 2020 (USD Million)
Figure 11.15 Funding and Investment Analysis: Distribution by Geography
Figure 11.16 Funding and Investment Analysis: Regional Distribution by Total Amount Invested, Pre-2014-Q1 2020
Figure 11.17 Most Active Players: Distribution by Number of Funding Instances and Amount Raised (USD Million)
Figure 11.18 Most Active Technologies: Distribution by Number of Funding Instances and Amount Raised (USD Million)
Figure 11.19 Most Active Investors: Distribution by Number of Funding Instances
Figure 11.20 Funding and Investment Summary, Pre-2014-Q1 2020 (USD Million)
Figure 12.1 Patent Portfolio: Distribution by Type of Patent
Figure 12.2 Patent Portfolio: Cumulative Distribution by Application Year, 2011-2019
Figure 12.3 Patent Portfolio: Distribution of Filed Patents by Application Year, 2011-2019
Figure 12.4 Patent Portfolio: Distribution of Granted Patents by Application Year, 2011-2019
Figure 12.5 Patent Portfolio: Distribution by Issuing Authority / Patent Offices Involved
Figure 12.6 Patent Portfolio: Distribution by CPC Symbols
Figure 12.7 Patent Portfolio: Emerging Focus Areas
Figure 12.8 Patent Portfolio: Cumulative Distribution by Type of Organization
Figure 12.9 Leading Patent Assignees: Distribution by Number of Patents
Figure 12.10 Patent Portfolio: Leading Non-Industry Players in Terms of Number of Patents
Figure 12.11 Patent Portfolio: Distribution by Patent Age (2000-2019)
Figure 12.12 Patent Portfolio: Distribution based on Proprietary Scoring Criteria
Figure 12.13 Patent Portfolio: Valuation Analysis
Figure 13.1 Commercial Development Strategies Adopted for Drug A
Figure 13.2 Commercial Development Strategies Adopted for Drug B
Figure 13.3 Commercial Development Strategies Adopted for Drug C
Figure 13.4 Commercial Development Strategies Adopted for Drug D
Figure 13.5 BBB Penetrating Drug Developers: Popular Development Strategies
Figure 14.1 Market Potential of Key Neurological Disorders: 3D Bubble Analysis based on Number of Approved Drugs, Pipeline Strength and Target Patient Population
Figure 14.2 Normal Brain versus Diseased Brain
Figure 14.3 Alzheimer’s Disease: Phases of Disease Progression
Figure 14.4 Global Dementia-Related Statistics: 2015 and 2030 (Millions)
Figure 14.5 Alzheimer’s Disease: Signs and Symptoms
Figure 14.6 Alzheimer’s Disease: Dietary Supplements
Figure 14.7 Market Potential of Alzheimer’s Disease: 3D Bubble Analysis based on Number of Approved Drugs, Pipeline Strength and Target Patient Population
Figure 14.8 Brain Cancer: Signs and Symptoms
Figure 14.9 Market Potential of Brain Cancer: 3D Bubble Analysis based on Number of Approved Drugs, Pipeline Strength and Target Patient Population
Figure 14.10 Multiple Sclerosis: Signs and Symptoms
Figure 14.11 Market Potential of Multiple Sclerosis: 3D Bubble Analysis based on Number of Approved Drugs, Pipeline Strength and Target Patient Population
Figure 14.12 Parkinson’s Disease: Causal Environmental Factors
Figure 14.13 Parkinson’s Disease: Gender-wise Incidence Rates
Figure 14.14 Parkinson’s Disease: Disease Stages
Figure 14.15 Parkinson’s Disease: Motor Symptoms
Figure 14.16 Parkinson’s Disease: Secondary Symptoms
Figure 14.17 Parkinson’s Disease Management: Non-Pharmacological Treatment Options
Figure 14.18 Parkinson’s Disease Management: Surgical Methods
Figure 14.19 Parkinson’s Disease Management: Dietary Supplements
Figure 14.20 Market Potential of Parkinson’s Disease: 3D Bubble Analysis based on Number of Approved Drugs, Pipeline Strength and Target Patient Population
Figure 16.1 Technology Licensing: Distribution of Financial Components
Figure 16.2 Technology Licensing: Likely Market Evolution
Figure 16.3 BBB Penetration Technologies: Average Volume and Value of Upfront Payments (Units, USD Million)
Figure 16.4 BBB Penetration Technologies: Average Volume and Value of Milestone Payments (Units, USD Million)
Figure 16.5 Overall BBB Penetration Technologies Market, 2020-2030 (USD Million)
Figure 16.6 Overall BBB Penetrating Drugs Market, 2020-2030 (USD Million)
Figure 16.7 BBB Penetrating Drugs Market: Distribution by Type of Molecule, 2020 and 2030
Figure 16.8 BBB Penetrating Drugs Market for Small Molecules, 2020-2030 (USD Million)
Figure 16.9 BBB Penetrating Drugs Market for Biologics, 2020-2030 (USD Million)
Figure 16.10 BBB Penetrating Drugs Market: Distribution by Target Disease Indication, 2020 and 2030
Figure 16.11 BBB Penetrating Drugs Market for Brain Metastases in Breast Cancer, 2020-2030 (USD Million)
Figure 16.12 BBB Penetrating Drugs Market for Glioblastoma Multiforme, 2020-2030 (USD Million)
Figure 16.13 BBB Penetrating Drugs Market for Hunter Syndrome, 2020-2030 (USD Million)
Figure 16.14 BBB Penetrating Drugs Market for Hurler Syndrome, 2020-2030 (USD Million)
Figure 16.15 BBB Penetrating Drugs Market: Distribution by Key Geographical Regions, 2020 and 2030
Figure 16.16 BBB Penetrating Drugs Market in North America, 2020-2030 (USD Million)
Figure 16.17 BBB Penetrating Drugs Market in Europe, 2020-2030 (USD Million)
Figure 16.18 BBB Penetrating Drugs Market in Asia-Pacific and Rest of the World, 2020-2030 (USD Million)
Figure 16.19 BBB Penetrating Drugs Market: Distribution by Leading Technology Platforms, 2020 and 2030
Figure 16.20 BBB Penetrating Drugs Market: Distribution by Leading Drug Developers, 2020 and 2030
Figure 16.21 2B3-101 / 2X-111 (2X Oncology): Sales Forecast, till 2030 (USD Million)
Figure 16.22 2B3-101 / 2X-111 (2X Oncology): Risk-Adjusted Market Opportunity, till 2030 (USD Million)
Figure 16.23 AGT-181 (ArmaGen): Sales Forecast, till 2030 (USD Million)
Figure 16.24 AGT-181 (ArmaGen): Risk-Adjusted Market Opportunity, till 2030 (USD Million)
Figure 16.25 AGT-182 (ArmaGen): Sales Forecast, till 2030 (USD Million)
Figure 16.26 AGT-182 (ArmaGen): Risk-Adjusted Market Opportunity, till 2030 (USD Million)
Figure 16.27 ANG1005 (Angiochem): Sales Forecast, till 2030 (USD Million)
Figure 16.28 ANG1005 (Angiochem): Risk-Adjusted Market Opportunity, till 2030 (USD Million)
Figure 16.29 JR-141 (JCR Pharmaceuticals): Sales Forecast, till 2030 (USD Million)
Figure 16.30 JR-141 (JCR Pharmaceuticals): Risk-Adjusted Market Opportunity, till 2030 (USD Million)

List Of Tables

Table 3.1 Key Components of the Human Brain
Table 3.2 Commercially Available Devices for CNS Drug Delivery
Table 3.3 Key Differences: Non-Invasive and Invasive BBB Technologies
Table 3.4 List of Key Constituents of the BBB
Table 3.5 Key Functions of the BBB
Table 3.6 List of Blood to Brain Transporters
Table 4.1 Non-Invasive BBB Penetration Technologies: List of Technology Platforms
Table 4.2 Non-Invasive BBB Penetration Technologies: List of Technology Providers
Table 5.1 BBB Penetrating Drugs: Development Pipeline
Table 5.2 BBB Penetrating Drugs: Additional Information
Table 5.3 BBB Penetrating Drugs: List of Drug Developers
Table 6.1 Non-Invasive BBB Penetration Technologies and Drugs: List of Companies Profiled
Table 6.2 Angiochem: Company Overview
Table 6.3 Angiochem: Product Portfolio
Table 6.4 Angiochem: Recent Developments and Future Outlook
Table 6.5 ArmaGen: Company Overview
Table 6.6 ArmaGen: Product Portfolio
Table 6.7 ArmaGen: Recent Developments and Future Outlook
Table 6.8 Denali Therapeutics: Company Overview
Table 6.9 Denali Therapeutics: Product Portfolio
Table 6.10 Denali Therapeutics: Recent Developments and Future Outlook
Table 6.11 ICB International: Company Overview
Table 6.12 ICB International: Product Portfolio
Table 6.13 ICB International: Recent Developments and Future Outlook
Table 6.14 Lauren Sciences: Company Overview
Table 6.15 Lauren Sciences: Product Portfolio
Table 6.16 Lauren Sciences: Recent Developments and Future Outlook
Table 6.17 BioArctic: Company Overview
Table 6.18 BioArctic: Product Portfolio
Table 6.19 BioArctic: Recent Developments and Future Outlook
Table 6.20 Cyclenium Pharma: Company Overview
Table 6.21 Cyclenium Pharma: Product Portfolio
Table 6.22 Cyclenium Pharma: Recent Developments and Future Outlook
Table 6.23 Iproteos: Company Overview
Table 6.24 Iproteos: Product Portfolio
Table 6.25 Iproteos: Recent Developments and Future Outlook
Table 6.26 Medesis Pharma: Company Overview
Table 6.27 Medesis Pharma: Product Portfolio
Table 6.28 Medesis Pharma: Recent Developments and Future Outlook
Table 6.29 Ossianix: Company Overview
Table 6.30 Ossianix: Product Portfolio
Table 6.31 Ossianix: Recent Developments and Future Outlook
Table 6.32 Vect-Horus: Company Overview
Table 6.33 Vect-Horus: Product Portfolio
Table 6.34 Vect-Horus: Recent Developments and Future Outlook
Table 6.35 JCR Pharmaceuticals: Company Overview
Table 6.36 JCR Pharmaceuticals: Product Portfolio
Table 6.37 JCR Pharmaceuticals: Recent Developments and Future Outlook
Table 9.1 Non-Invasive BBB Penetration Technologies and Drugs: Partnerships and Collaborations, Information on Partnership Type, Year and Type of Partner, till Q1 2020
Table 9.2 Non-Invasive BBB Penetration Technologies and Drugs: Partnerships and Collaborations, Information on Type of Molecule, Target Indication and Focus Area, till Q1 2020
Table 10.1 List of BBB-Related Technology Licensing Agreements, till Q1 2020
Table 10.2 Licensing Agreement Details: Sumitomo Dainippon Pharma and JCR Pharmaceuticals
Table 10.3 Licensing Agreement Details: Denali Therapeutics and Sanofi
Table 10.4 Licensing Agreement Details: biOasis Technologies and Prothena
Table 10.5 Licensing Agreement Details: Vect-Horus and Janssen Pharmaceuticals
Table 11.1 Non-Invasive BBB Penetration Technologies and Drugs: Funding and Investments, Information on Funding Type, Year, Amount and Investor, till Q1 2020
Table 11.2 Non-Invasive BBB Penetration Technologies and Drugs: Funding and Investments, Information on Type of Molecule, Target Indication and Focus Area, till Q1 2020
Table 12.1 Patent Portfolio: Definitions of CPC Symbols
Table 12.2 Patent Portfolio: Most Popular CPC Symbols
Table 14.1 Alzheimer’s Disease: List of Marketed Drugs
Table 14.2 Alzheimer’s Disease: List of BBB Penetrating Drugs
Table 14.3 Brain Cancer: List of Marketed Drugs
Table 14.4 Brain Cancer: List of BBB Penetrating Drugs
Table 14.5 Multiple Sclerosis: List of Marketed Drugs
Table 14.6 Multiple Sclerosis: List of BBB Penetrating Drugs
Table 14.7 Parkinson’s Disease: List of Marketed Drugs
Table 14.8 Parkinson’s Disease: List of BBB Penetrating Drugs
Table 15.1 Opportunities in North America: Most Likely Partners
Table 15.2 Opportunities in North America: Likely Partners
Table 15.3 Opportunities in North America: Less Likely Partners
Table 15.4 Opportunities in Europe: Most Likely Partners
Table 15.5 Opportunities in Europe: Likely Partners
Table 15.6 Opportunities in Europe: Less Likely Partners
Table 15.7 Opportunities in Asia-Pacific and Rest of the World: Most Likely Partners
Table 15.8 Opportunities in Asia-Pacific and Rest of the World: Likely Partners
Table 15.9 Opportunities in Asia-Pacific and Rest of the World: Less Likely Partners
Table 16.1. Technology Licensing Agreements: Tranches of Milestone Payments
Table 16.2. BBB-Related Technology Licensing Agreements: Average Upfront Payments and Average Milestone Payments, Pre-2014-Q1 2020 (USD Million)
Table 16.3. BBB Penetrating Drugs: Promising Drug Candidates
Table 16.4. BBB Penetrating Drugs Forecast Assumptions: Price Estimations in Key Geographies
Table 16.5. 2B3-101 / 2X-111 (2X Oncology): Net Present Value (USD Million)
Table 16.6. 2B3-101 / 2X-111 (2X Oncology): Value Creation Analysis (USD Million)
Table 16.7. AGT-181 (ArmaGen): Net Present Value (USD Million)
Table 16.8. AGT-181 (ArmaGen): Value Creation Analysis (USD Million)
Table 16.9. AGT-182 (ArmaGen): Net Present Value (USD Million)
Table 16.10. AGT-182 (ArmaGen): Value Creation Analysis (USD Million)
Table 16.11. ANG1005 (Angiochem): Net Present Value (USD Million)
Table 16.12. ANG1005 (Angiochem): Value Creation Analysis (USD Million)
Table 16.13. JR-141 (JCR Pharmaceuticals): Net Present Value (USD Million)
Table 16.14. JR-141 (JCR Pharmaceuticals): Value Creation Analysis (USD Million)
Table 17.1 BBB Penetrating Drugs and Technologies: Key Takeaways of the Report
Table 18.1 ICBI: Company Snapshot
Table 18.2 Ossianix: Company Snapshot
Table 18.3 2-BBB: Company Snapshot
Table 18.4 ArmaGen: Company Snapshot
Table 18.5 biOasis Technologies: Company Snapshot
Table 18.6 Cyclenium Pharma: Company Snapshot
Table 18.7 Sagetis Biotech: Company Snapshot
Table 18.8 CarThera: Company Snapshot
Table 18.9 Vect-Horus: Company Snapshot
Table 18.10 Wyss Institute, Harvard University: Company Snapshot
Table 19.1 Important Statistics Related to Neurological Disorders
Table 19.2 Non-Invasive BBB Penetration Technologies: Distribution by Status of Development
Table 19.3 Non-Invasive BBB Penetration Technologies: Distribution by Underlying Principle
Table 19.4 Non-Invasive BBB Penetration Technologies: Distribution by Compatible Pharmacological Molecule(s)
Table 19.5 Non-Invasive BBB Penetration Technologies: Distribution by Target Receptor(s)
Table 19.6 Non-Invasive BBB Penetration Technologies: Distribution by Target Disease Indication(s)
Table 19.7 Non-Invasive BBB Penetration Technologies: Distribution by Patent Availability
Table 19.8 Non-Invasive BBB Penetration Technologies: Distribution by Licensing Activity
Table 19.9 Non-Invasive BBB Technology Providers: Distribution by Year of Establishment
Table 19.10 Non-Invasive BBB Technology Providers: Distribution by Company Size
Table 19.11 Non-Invasive BBB Technology Providers: Distribution by Location of Headquarters
Table 19.12 BBB Penetrating Drugs: Distribution by Phase of Development
Table 19.13 BBB Penetrating Drugs: Distribution by Type of Molecule
Table 19.14 BBB Penetrating Drugs: Distribution by Affiliated BBB Penetration Technology
Table 19.15 BBB Penetrating Drugs: Distribution by Route of Administration
Table 19.16 BBB Penetrating Drugs: Distribution by Target Disease Indication(s)
Table 19.17 BBB Penetrating Drugs: Distribution by Therapeutic Area(s)
Table 19.18 BBB Penetrating Drug Developers: Distribution by Year of Establishment
Table 19.19 BBB Penetrating Drug Developers: Distribution by Company Size
Table 19.20 BBB Penetrating Drug Developers: Distribution by Location of Headquarters
Table 19.21 Leading Drug Developers: Distribution by Number of Drugs
Table 19.22 Heptagon Representation: Distribution by Phase of Development and Key Disease Indications
Table 19.23 Tree Map Representation: Distribution by Key Disease Indications and Size of the Company
Table 19.24 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre--2014-Q1 2020
Table 19.25 Partnerships and Collaborations: Distribution by Type of Partnership
Table 19.26 Partnerships and Collaborations: Year-Wise Trend by Type of Partnership
Table 19.27 Partnerships and Collaborations: Distribution by Type of Partner
Table 19.28 Partnerships and Collaborations: Year-Wise Trend by Type of Partner
Table 19.29 Partnerships and Collaborations: Distribution by Type of Partner and Partnership Model
Table 19.30 Partnerships and Collaborations: Distribution by Focus Area
Table 19.31 Partnerships and Collaborations: Distribution by Type of Molecule
Table 19.32 Partnerships and Collaborations: Year-Wise Trend by Type of Molecule
Table 19.33 Partnerships and Collaborations: Distribution by Target Disease Indication
Table 19.34 Partnerships and Collaborations: Year-Wise Trend by Target Disease Indication
Table 19.35 Partnerships and Collaborations: Distribution by Target Disease Indication and Partnership Model
Table 19.36 Most Active Players: Distribution by Number of Partnerships
Table 19.37 Most Popular Technologies: Distribution by Number of Partnerships
Table 19.38 Partnerships and Collaborations: Regional Distribution
Table 19.39 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 19.40 BBB-Related Technology Licensing Agreements: Cumulative Year-Wise Trend, Pre-2014-Q1 2020
Table 19.41 BBB-Related Technology Licensing Agreements: Distribution by Type of Licensing Agreement
Table 19.42 BBB-Related Technology Licensing Agreements: Distribution by Type of Owner
Table 19.43 Most Active Players: Distribution by Number of Licensing Agreements
Table 19.44 BBB-Related Technology Licensing Agreements: Regional Analysis
Table 19.45 BBB-Related Technology Licensing Agreements: Intercontinental and Intracontinental Agreements
Table 19.46 Funding and Investment Analysis: Distribution of Companies by Year of Establishment and Type of Funding, Pre-2014-Q1 2020
Table 19.47 Funding and Investment Analysis: Cumulative Number of Instances by Year, Pre-2014-Q1 2020
Table 19.48 Funding and Investment Analysis: Distribution by Type of Funding and Year of Investment, Pre-2014-Q1 2020
Table 19.49 Funding and Investment Analysis: Cumulative Amount Invested, Pre-2014-Q1 2020 (USD Million)
Table 19.50 Funding and Investment Analysis: Year-Wise Distribution by Amount Invested and Type of Funding, Pre-2014-Q1 2020 (USD Million)
Table 19.51 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Pre-2014-Q1 2020
Table 19.52 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, Pre-2014-Q1 2020 (USD Million)
Table 19.53 Funding and Investment Analysis: Distribution by Total Amount Invested and Type of Company, Pre-2014-Q1 2020 (USD Million)
Table 19.54 Funding and Investment Analysis: Distribution of the Total Amount Invested by Purpose of Funding, Pre-2014-Q1 2020 (USD Million)
Table 19.55 Funding and Investment Analysis: Distribution of Instances by Type of Molecule, Pre-2014-Q1 2020
Table 19.56 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Molecule, Pre-2014-Q1 2020 (USD Million)
Table 19.57 Funding and Investment Analysis: Distribution by Target Disease Indication
Table 19.58 Funding and Investment Analysis: Distribution of the Total Amount Invested by Target Disease Indication, Pre-2014-Q1 2020 (USD Million)
Table 19.59 Funding and Investment Analysis: Distribution by Geography
Table 19.60 Funding and Investment Analysis: Regional Distribution by Total Amount Invested, Pre-2014-Q1 2020
Table 19.61 Most Active Players: Distribution by Number of Funding Instances and Amount Raised (USD Million)
Table 19.62 Most Active Technologies: Distribution by Number of Funding Instances and Amount Raised (USD Million)
Table 19.63 Most Active Investors: Distribution by Number of Funding Instances
Table 19.64 Funding and Investment Summary, Pre-2014-Q1 2020 (USD Million)
Table 19.65 Patent Portfolio: Distribution by Type of Patent
Table 19.66 Patent Portfolio: Cumulative Distribution by Application Year, 2011-2019
Table 19.67 Patent Portfolio: Distribution of Filed Patents by Application Year, 2011-2019
Table 19.68 Patent Portfolio: Distribution of Granted Patents by Application Year, 2011-2019
Table 19.69 Patent Portfolio: Distribution by Issuing Authority / Patent Offices Involved
Table 19.70 Patent Portfolio: Distribution by CPC Symbols
Table 19.71 Patent Portfolio: Cumulative Distribution by Type of Organization
Table 19.72 Leading Patent Assignees: Distribution by Number of Patents
Table 19.73 Patent Portfolio: Leading Non-Industry Players in Terms of Number of Patents
Table 19.74 Patent Portfolio: Distribution by Patent Age (2000-2019)
Table 19.75 Patent Portfolio: Valuation Analysis
Table 19.76 Global Dementia-Related Statistics: 2015 and 2030 (Millions)
Table 19.77 BBB Penetration Technologies: Average Volume and Value of Upfront Payments (Units, USD Million)
Table 19.78 BBB Penetration Technologies: Average Volume and Value of Milestone Payments (Units, USD Million)
Table 19.79 Overall BBB Penetration Technologies Market, Conservative, Base and Optimistic Scenario, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.80 Overall BBB Penetrating Drugs Market, Conservative, Base and Optimistic Scenario, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.81 BBB Penetrating Drugs Market: Distribution by Type of Molecule, 2020 and 2030
Table 19.82 BBB Penetrating Drugs Market for Small Molecules, Conservative, Base and Optimistic Scenario, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.83 BBB Penetrating Drugs Market for Biologics, Conservative, Base and Optimistic Scenario, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.84 BBB Penetrating Drugs Market: Distribution by Target Disease Indication, 2020 and 2030
Table 19.85 BBB Penetrating Drugs Market for Brain Metastases in Breast Cancer, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.86 BBB Penetrating Drugs Market for Glioblastoma Multiforme, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.87 BBB Penetrating Drugs Market for Hunter Syndrome, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.88 BBB Penetrating Drugs Market for Hurler Syndrome, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.89 BBB Penetrating Drugs Market: Distribution by Key Geographical Regions, 2020 and 2030
Table 19.90 BBB Penetrating Drugs Market in North America, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.91 BBB Penetrating Drugs Market in Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.92 BBB Penetrating Drugs Market in Asia-Pacific and Rest of the World, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.93 BBB Penetrating Drugs Market: Distribution by Leading Technology Platforms, 2020 and 2030
Table 19.94 BBB Penetrating Drugs Market: Distribution by Leading Drug Developers, 2020 and 2030
Table 19.95 2B3-101 / 2X-111 (2X Oncology): Sales Forecast, till 2030 (USD Million)
Table 19.96 2B3-101 / 2X-111 (2X Oncology): Risk-Adjusted Market Opportunity, till 2030 (USD Million)
Table 19.97 AGT-181 (ArmaGen): Sales Forecast, till 2030 (USD Million)
Table 19.98 AGT-181 (ArmaGen): Risk-Adjusted Market Opportunity, till 2030 (USD Million)
Table 19.99 AGT-182 (ArmaGen): Sales Forecast, till 2030 (USD Million)
Table 19.100 AGT-182 (ArmaGen): Risk-Adjusted Market Opportunity, till 2030 (USD Million)
Table 19.101 ANG1005 (Angiochem): Sales Forecast, till 2030 (USD Million)
Table 19.102 ANG1005 (Angiochem): Risk-Adjusted Market Opportunity, till 2030 (USD Million)
Table 19.103 JR-141 (JCR Pharmaceuticals): Sales Forecast, till 2030 (USD Million)
Table 19.104 JR-141 (JCR Pharmaceuticals): Risk-Adjusted Market Opportunity, till 2030 (USD Million)

Listed Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 2-BBB
  2. 2X Oncology 
  3. 4P Therapeutics
  4. AB Science
  5. Abbott
  6. AbbVie 
  7. Ablynx
  8. AC Immune
  9. ACADIA Pharmaceuticals
  10. Accera
  11. Acelot
  12. Acorda Therapeutics
  13. Actinogen Medical
  14. Acumen Pharmaceuticals
  15. Adamas Pharmaceuticals
  16. Addex Therapeutics
  17. Advanced Accelerator Applications 
  18. Advanced BioHealing
  19. Aeolus Pharmaceuticals
  20. Aescap Ventures
  21. Aestas Pharma
  22. Affectis Pharmaceuticals
  23. AFFiRiS
  24. Agate Medical Investments
  25. AgeneBio 
  26. Agoranov
  27. AiCuris
  28. Aix-Marseille University
  29. Alaska Permanent Fund
  30. Alcyone Lifesciences
  31. Alector
  32. Alkahest
  33. Allergan
  34. Allinky Biopharma
  35. Alnylam Pharmaceuticals
  36. Alzinova
  37. AlzProtect
  38. AMAbiotics
  39. Amarantus Therapeutics
  40. American Cancer Society
  41. American Life Science Pharmaceuticals
  42. Amgen
  43. Amylyx Pharmaceuticals
  44. Anavex Life Sciences
  45. Angiochem
  46. Antea Group
  47. Antoxis 
  48. Aphios
  49. ApoPharma
  50. APRINOIA Therapeutics
  51. Araclon Biotech
  52. Arbor Pharmaceuticals 
  53. ARCH Venture Partners
  54. Archer Pharmaceuticals
  55. ArmaGen
  56. ARMGO Pharma
  57. ArQule
  58. Array BioPharma
  59. Arrien Pharmaceuticals
  60. Arrowhead Pharmaceuticals
  61. Artenga
  62. Asceneuron
  63. ASCIL Biopharm
  64. ASEBIO
  65. Astellas Pharma
  66. AstraZeneca
  67. Atlas Venture
  68. aTyr Pharma
  69. Aurin Biotech
  70. Ausio Pharmaceuticals
  71. Autifony Therapeutics
  72. Avanir Pharmaceuticals
  73. Axon Neuroscience
  74. Axovant Sciences
  75. Axsome Therapeutics
  76. AZTherapies
  77. Bach Pharma
  78. Baillie Gifford
  79. Baxter Healthcare
  80. Bayer
  81. BBB Therapeutics
  82. BDC Venture Capital
  83. BELLUS Health 
  84. BenevolentAI Bio
  85. Ben-Gurion University
  86. BGN Technologies
  87. BIAL Group
  88. BIND Therapeutics
  89. BioAdvance
  90. BioAgilytix 
  91. BioArctic
  92. biOasis Technologies
  93. Biocat
  94. Biocrea
  95. BioElectronics
  96. Biogen
  97. Biohaven
  98. BioLineRx
  99. BioMarin
  100. Bionomics
  101. Biotie Therapies
  102. Biovista
  103. BlueRock Therapeutics
  104. Boehringer Ingelheim
  105. Boehringer Ingelheim Venture Fund
  106. Boston Scientific
  107. BpiFrance
  108. Brain Biomarker Solutions
  109. Brains for Brain Foundation
  110. BrainsGate
  111. BrainStorm Cell Therapeutics
  112. BrainVectis
  113. BrainX
  114. Brisco Capital Partners
  115. Bristol-Myers Squibb 
  116. Britannia Pharmaceuticals
  117. Broad Institute
  118. CAAP Creation
  119. Caixa Capital Risc
  120. Cantabio Pharmaceuticals
  121. Capo Therapeutics
  122. Carna Biosciences
  123. CarThera
  124. Cellix Bio
  125. Cenna Biosciences
  126. CENTOGENE
  127. Cerecin (formerly called Accera)
  128. Cerecor
  129. CereSpir
  130. Cerevance
  131. CHA Biotech 
  132. Changchun Huayang High-tech
  133. Chaperone Therapeutics
  134. Chipscreen
  135. Chronos Therapeutics
  136. CinnaGen
  137. Cipio Partners
  138. Clera
  139. Clevexel
  140. CNRS Innovation
  141. Cobra Biologics 
  142. Cogentis Therapeutics
  143. Cognition Therapeutics
  144. Cognosci
  145. Collaborative Medicinal Development
  146. Columbia University
  147. Contera Pharma
  148. CoPlex Therapeutics
  149. Corium International
  150. Cornell University
  151. Cortexyme
  152. Cortice Biosciences
  153. Corvitex
  154. Crinetics Pharmaceuticals
  155. CuraSen Therapeutics
  156. Curemark
  157. Cyclenium Pharma 
  158. DAE HWA Pharmaceutical
  159. Daewoong Pharmaceutical
  160. Dainippon Sumitomo Pharma
  161. Dart Pharma
  162. Debiopharm
  163. Deciphera Pharmaceuticals
  164. DEKK-TEC
  165. DelMar Pharmaceuticals
  166. Denali Therapeutics
  167. DermaXon
  168. Dexcom
  169. Domain Therapeutics 
  170. Dong-A ST
  171. Edunn Biotechnology
  172. Eight Roads Ventures
  173. EIP Pharma
  174. Eisai
  175. Elan Pharmaceuticals
  176. Eli Lilly 
  177. Elron Electronic Industries
  178. EMD Serono
  179. EMulate Therapeutics 
  180. EnhanX Biopharm
  181. Enterin
  182. E-Scape Bio
  183. Ethris
  184. Eureka Eurostars
  185. Evercore
  186. Evgen Pharma
  187. Fabre-Kramer Pharmaceutical
  188. Federal Ministry of Education and Research
  189. FerroKin BioSciences
  190. Fidelity Biosciences
  191. FightMND
  192. Financière Tuileries
  193. Flagship Ventures 
  194. Flocel
  195. Fluorinov Pharma
  196. Fondazione Telethon
  197. Forest laboratories (a division of Allergan)
  198. F-star
  199. FUJIFILM Toyama Chemical
  200. Fulcrum Therapeutics
  201. Fundación MEDINA
  202. Gale Capital Solutions
  203. GemVax & KAEL
  204. Gene Therapy Research Institution
  205. Genentech
  206. Genervon Biopharmaceuticals
  207. Genzyme
  208. German Cancer Research Center
  209. Gismo Therapeutics
  210. GlaxoSmithKline
  211. GliaCure
  212. GliaPharm
  213. GNT Pharma
  214. Goldman Sachs
  215. Grifols
  216. Groupe Arnault 
  217. Halozyme Therapeutics
  218. Haplogen
  219. Harvard University
  220. Herantis Pharma
  221. Heritage Pharmaceuticals
  222. HSRx Biopharmaceutical
  223. IACTA Pharmaceuticals
  224. Innovative California Biosciences International 
  225. Il Dong Pharmaceutical
  226. Immune Pharmaceuticals
  227. Immunex
  228. Immungenetics
  229. Impax Laboratories
  230. Impel NeuroPharma
  231. ImStar
  232. Industrial Technology Research Institute
  233. Inflazome
  234. Inhibikase Therapeutics
  235. Innovate UK
  236. Innovative California Biosciences International (ICBI)
  237. INSERM-CEA
  238. Institute for Research in Immunology and Cancer — Commercialization of Research
  239. Intec Pharma
  240. Integrative Research Laboratories
  241. IntelGenx
  242. Intellect Neurosciences
  243. International Stem Cell
  244. Intra-Cellular Therapies
  245. INVENT Pharmaceuticals
  246. Io Therapeutics
  247. Ionis Pharmaceuticals
  248. Iproteos
  249. IRB Barcelona
  250. Janssen Pharmaceuticals 
  251. Jazz Pharmaceuticals
  252. JCR Pharmaceuticals
  253. JEIL Pharmaceuticals
  254. Johns Hopkins University
  255. Johnson & Johnson 
  256. Johnson and Johnson Development
  257. Jonghoud International
  258. Junaxo
  259. Kadmon
  260. Kainos Medicine
  261. KalGene Pharmaceuticals
  262. Karuna Pharmaceuticals
  263. Khondrion
  264. Kinled Holding
  265. Kissei Pharmaceutical
  266. Korea Drug Development Fund (KDDF)
  267. K-PAX Pharmaceuticals
  268. Krisani Bio
  269. Kyowa Hakko Kirin
  270. Lauren Sciences
  271. Leland Stanford Junior University
  272. Leiden University
  273. Lipopharma
  274. Living Cell Technologies
  275. Lixte Biotechnology
  276. Longeveron
  277. Longevity Biotech
  278. Lonza
  279. Lotus Tissue 
  280. Lumena Pharmaceuticals
  281. Lundbeck 
  282. Luye Pharma Group
  283. Lyndra Therapeutics
  284. Lysosomal Therapeutics
  285. M3 Biotechnology
  286. Massachusetts Institute of Technology
  287. McGill University 
  288. Med-Life Discoveries
  289. MedDay Pharmaceuticals
  290. Medesis Pharma
  291. MedGenesis Therapeutix
  292. MedImmune
  293. MEDIPOST
  294. Mediti Pharma
  295. Medtronic
  296. Melior Pharmaceuticals
  297. Merck
  298. Metabolic Solutions Development Company
  299. Michael J Fox Foundation
  300. Michael Smiths Laboratories
  301. Minerva Neurosciences
  302. Minoryx Therapeutics
  303. Mireca Medicines
  304. Mission Therapeutics
  305. Mitochon Pharmaceuticals
  306. Mitsui Global Investment
  307. MMV Financial
  308. Moderna Therapeutics
  309. Momenta Pharmaceuticals
  310. Montisera
  311. Morgan Stanley
  312. Morphotek
  313. Movetis
  314. Mylan
  315. Mylan Laboratories
  316. Mystic Pharmaceuticals
  317. naNO LIMIT Therapeutics
  318. Nanomerics
  319. National Cancer Institute 
  320. National Multiple Sclerosis Society
  321. Nektar Therapeutics
  322. Neomed Institute of Wellness and Rehabilitation
  323. Netherlands Translational Research Center
  324. Neuralstem 
  325. Neuraltus Pharmaceuticals
  326. Neuren Pharmaceuticals
  327. Neurim Pharmaceuticals
  328. NeuroAdjuvants
  329. Neurocentria
  330. Neurocrine Biosciences 
  331. NeuroDerm
  332. Neurodon
  333. Neurogeneration
  334. NeuroGenetic Pharmaceuticals
  335. Neurolixis
  336. Neuron Bio
  337. NeuroNascent
  338. Neuronix
  339. NeurOp
  340. Neuropore Therapies
  341. NeuroSolis
  342. Neurotez
  343. NeuroTransit
  344. Neurotrope Bioscience
  345. NeuroVive Pharmaceutical
  346. NEUWAY Pharma
  347. New World Laboratories
  348. NewGen Therapeutics
  349. NexGenix
  350. NextSource Biotechnology
  351. nLife Therapeutics
  352. NLS Pharma
  353. Nordic Life Sciences
  354. Novartis
  355. Novo Nordisk
  356. Novogen
  357. NPS Pharmaceuticals
  358. Nsgene
  359. Oligomerix
  360. Oncodesign
  361. OncoNanoBBB
  362. Ono Pharmaceutical
  363. OPKO Health
  364. OptiNose
  365. Orion Pharma
  366. Ortho-McNeil Pharmaceutical
  367. Oryzon Genomics
  368. Osmotica Pharmaceutical
  369. Ossianix
  370. Otsuka Pharmaceutical
  371. Oxalys Pharmaceuticals
  372. Oxford BioMedica
  373. P2D Bioscience 
  374. Pain Therapeutics
  375. Palobiofarma
  376. Panakès Partners
  377. Pangu BioPharma
  378. Parc Cientific de Barcelona
  379. Parke-Davis
  380. PeptiDream 
  381. Peptron
  382. Perfusion Technology
  383. Pervasis Therapeutics
  384. Pfizer
  385. Pharma Two B
  386. Pharmacia & Upjohn
  387. Pharmaphenix
  388. Pharmidex
  389. Pharnext 
  390. Pitango Venture Capital
  391. Plex Pharmaceuticals
  392. Plexxikon
  393. Portage Pharmaceuticals
  394. Prana Biotechnology
  395. Premacure
  396. Prexton Therapeutics
  397. Priavoid
  398. Primary Peptides
  399. Proclara Biosciences
  400. ProMIS Neurosciences
  401. Promius Pharma
  402. Protagenic Therapeutics
  403. ProteoTech
  404. Prothena
  405. Protheragen 
  406. PTC Therapeutics
  407. QR Pharma
  408. Radio Medix
  409. Radius Health
  410. Raptor
  411. RaQualia Pharma
  412. Regenera Pharma
  413. RemeGenix
  414. reMYND
  415. Repligen
  416. Retrotope
  417. Rett Syndrome Research Trust
  418. Reviva Pharmaceuticals
  419. Roche
  420. Rodin Therapeutics
  421. SAGE Therapeutics
  422. Sagetis Biotech
  423. SalubRx Therapeutics
  424. Sandoz
  425. Sangamo Therapeutics
  426. Saniona
  427. Sanofi
  428. Santaris Pharma
  429. Saol Therapeutics
  430. Schering
  431. Schering-Plough
  432. Schwarz Pharma
  433. SciFluor Life Sciences
  434. SCR Provençale et Corse 
  435. Serina Therapeutics
  436. Servier
  437. Sham Innovation Santé
  438. Shanghai Green valley Pharmaceutical
  439. Shire
  440. Siena Biotech
  441. Sihuan Pharmaceutical
  442. SiMPore
  443. SiNON Therapeutics (formerly known as nano LIMIT Therapeutics)
  444. Sinphar Pharmaceutical
  445. SK Biopharmaceuticals
  446. SmithKline Beecham
  447. Solvo Biotechnology
  448. Sosei Heptares
  449. Southern Research
  450. Sovicell
  451. Spark Therapeutics
  452. Stern Investor Relations
  453. Sumitomo Dainippon Pharma
  454. Sun Pharma Advanced Research Company
  455. Sunovion
  456. Supernova Invest
  457. Suven Life Sciences
  458. Synageva BioPharma
  459. Synapse Technologies
  460. SynVivo
  461. T3D Therapeutics
  462. Tactical Therapeutics
  463. Takeda Pharmaceuticals
  464. Takeda Ventures
  465. TauRx Therapeutics
  466. TechnoPhage
  467. Teikoku Pharma
  468. Tetra Therapeutics
  469. Teva Pharmaceutical
  470. The ALS Association
  471. The Campbell Foundation
  472. The Hospital for Sick Children (SickKids)
  473. Titan Pharmaceuticals
  474. Tonix Pharmaceuticals
  475. TPG Biotech
  476. TransBioTech
  477. Transgene
  478. Transition Therapeutics
  479. TransMolecular
  480. Treventis
  481. TTY Biopharm
  482. UCB
  483. United Neuroscience
  484. University College London
  485. University of Barcelona
  486. University of British Columbia
  487. University of California
  488. University of Connecticut
  489. University of Sherbrooke
  490. University of Texas
  491. University of Washington
  492. Uppsala University
  493. US WorldMeds
  494. Vall d’Hebron Research Institute
  495. Vect-Horus
  496. VIMAC Milestone Medica Fund
  497. Vinnova
  498. ViroPharma
  499. VistaGen Therapeutics
  500. Vivreon Biosciences
  501. Vivoryon Therapeutics
  502. Voices Against Brain Cancer
  503. VoltMed
  504. Voyager Therapeutics
  505. Wellington Partners
  506. WuXi Biologics
  507. Xcelthera
  508. Xenoport
  509. Xinogen
  510. Xoc Pharmaceuticals
  511. Zambon
  512. Zywie

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com